T-cell infiltration, enhanced interferon-γ signaling, enrichment of tertiary lymphoid structure signatures, and upregulation of immune effector genes. Functional enrichment analyses further linked CEACAM1 to immune-related pathways, including inflammatory response, interferon signaling, and apoptosis. At the therapeutic level, CEACAM1 expression was associated with reduced sensitivity to multiple chemotherapeutic agents, while concurrently correlating with enrichment of immunotherapy-responsive gene signatures, indicating a distinct immune-active yet therapeutically heterogeneous subtype of SARC. Collectively, these findings suggest that CEACAM1 represents a potential biomarker of immune activation and therapeutic stratification in SARC, warranting further investigation as a predictive indicator and immunotherapy-related target in mesenchymal malignancies.
Cao et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: